Which drugs go off patent in 2035?
Two blockbuster drugs with $11.2B in 2025 worldwide sales lose US exclusivity in 2035, led by Prevnar 20 (Pfizer, $6.5B). One is a biologic that faces biosimilars and one is a vaccine.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Prevnar 20 | Pfizer | Vaccines | $6.5B | Company guidance | No US filing found | – |
| Ultomiris | AstraZeneca | Other | $4.7B | Company guidance | No US filing found | – |
Every date here is fixed by a launch, settlement, court ruling or company guidance. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Pfizer | Prevnar 20 | $6.5B | 10% |
| AstraZeneca | Ultomiris | $4.7B | 8% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer. Vaccines are hard to copy, so competition after exclusivity ends usually arrives slowly.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →